Radiotherapy is enhanced by CPH:SA IL-1α microparticles in a murine HNSCC tumor model
This data suggests that the addition of CPH:SA IL-1αMPs to RT may boost anti-tumor immune response and target both local and systemic disease. This combination is worthy of further investigation as an immunotherapeutic strategy and could represent a promising approach to improve survival outcomes in HNSCC patients.
Authors
- Aliasger K. Salem (ORCID: https://orcid.org/0000-0002-1923-6633)
- M.M. Hasibuzzaman (ORCID: https://orcid.org/0000-0002-0081-6742)
- Rui He (ORCID: https://orcid.org/0000-0003-3950-118X)
- Andrean L. Simons
- Ishrat Nourin Khan
Institutions
- University of Iowa (US)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1186/s12885-025-13995-3
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Veterans Affairs